US-based contract research organisation (CRO) PPD continues to expand the global footprint for its Phase II-IV clinical trial services, announcing a new appointment to drive expansion on the Indian subcontinent and opening a second office in Mumbai, India.

PPD recently divided its Phase II-IV operational units into four distinct territories (North America; Latin America; Europe, the Middle East and Africa; and Asia) and opened new offices in Australia, Denmark, Portugal and Peru. The latest step in the CRO’s internationalisation programme is to appoint Dr Philip Mathew, former associate medical director at Covance, as director of strategic development to lead PPD’s Phase II-IV operations and expansion in the fast-growing Indian market.

With the new Mumbai office as his base, Dr Mathew will provide strategic leadership for PPD’s drug development business on the Indian subcontinent, including clinical project management and patient recruitment, the CRO said. He will also be responsible for identifying and helping to develop new clinical sites and business opportunities as well as liaising with local and national government departments.

“A native of India, Dr Mathew brings extensive clinical trials experience and in-depth knowledge of the healthcare industry in this country,” commented Simon Britton, recently appointed vice-president of clinical operations for PPD in Asia. “His leadership will enable us to strengthen our presence in this important global clinical research market as we continue to meet the growing needs of our clients.”